CHAPEL HILL, N.C. - New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process. The study, published by Cell Press in the January issue of the journal Cancer Cell, provides a solid framework for investigation of future targeted therapies that may improve the near uniformly fatal prognosis of this devastating cancer.
"Previous work has established that gene expression profiling can be used to identify distinct subgroups of GBM," says senior study author, Dr. D. Neil Hayes from the Division of Hematology/Oncology at the University of North Carolina at Chapel Hill. "However, the exact number and clinical significance of these was unclear." Dr. Hayes and colleagues at UNC Lineberger expanded on previous GBM classification studies and used expression profiling techniques to comprehensively analyze hundreds of GBM patient samples. The group was able to reliably identify four distinct molecular subtypes of GBM tumors.
The researchers, part of the National Institutes of Health's The Cancer Genome Atlas (TCGA) Research Network, then went on to perform a unique integrative analyses across multiple platforms to look for defining characteristics associated with each subtype. Their findings were quite striking, implying that there are distinct types of GBM and that each one is associated with a specific molecular process. "We discovered a bundle of events that unequivocally occur almost exclusively within a subtype," explains Dr. Hayes.
The researchers also report that the nature of these events indicate that the underlying disease process for each subtype may involve distinct cells of origin at a specific stage of differentiation. This is finding has potential clinical significance as determining the cells of origin of GBM is critical for establishing effective treatment regimens. Clearly, given this new information, it makes sense that some drug classes would be expected to work for some tumor subtypes and not other. In support of this conclusion, Dr. Hayes's group found that response to aggressive chemotherapy and radiation differed by subtype.
Taken together, the findings represent an important step towards more rational therapies for GBM. "It appears that the simple classification into these four subtypes carries a rich set of associations for which there is no existing diagnostic test," says Dr. Hayes "This comprehensive genomic and genetic-based classification of GBM should lay the groundwork from an improved molecular understanding of GBM pathway signaling that could ultimately result in personalized therapies for groups of patients with GBM."
Significant work on this project was shared by TCGA researchers, Dr. Roel Verhaak of the Broad Institute of MIT and Harvard in Boston and Dr. Katie Hoadley of UNC Lineberger and the Department of Genetics at UNC-Chapel Hill. Other UNC Lineberger team members include postdoctoral fellow Matthew Wilkerson, Dr. Ryan Miller, and Dr. Charles M. Perou. Other collaborating institutions include the Dana-Farber Cancer Institute in Boston, MA; The Genome Center at Washington University School of Medicine in St. Louis; MO, the Lawrence Berkeley national Laboratory in Berkeley, CA; the University of California, San Francisco; Mayo Clinic, Rochester, MN; SRA International, Fairfax, VA; and the Walter and Eliza Hall Institute, Victoria, Australia.
See additional coverage on The Cancer Genome Atlas website.